Seer, Inc. (SEER)
| Market Cap | 109.17M |
| Revenue (ttm) | 16.58M |
| Net Income (ttm) | -73.60M |
| Shares Out | 56.42M |
| EPS (ttm) | -1.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 351,534 |
| Open | 1.970 |
| Previous Close | 1.950 |
| Day's Range | 1.940 - 1.970 |
| 52-Week Range | 1.650 - 2.410 |
| Beta | 1.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 8, 2026 |
About SEER
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers ... [Read more]
Financial Performance
In 2025, Seer, Inc.'s revenue was $16.58 million, an increase of 16.99% compared to the previous year's $14.17 million. Losses were -$73.60 million, -15.01% less than in 2024.
Financial StatementsNews
Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group
REDWOOD CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced tha...
The Radoff-JEC Group Submits Improved Non-Binding Proposal to Acquire Seer, Inc.
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 7.6% of the outstanding shares of ...
Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group
REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed tha...
The Radoff-JEC Group Submits Non-Binding Proposal to Acquire Seer, Inc.
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 7.6% of the outstanding shares of ...
Seer and Precision Health Research, Singapore Sign Collaboration to Provide Deep, Unbiased Proteomics on 10,000 PRECISE SG100K Samples
REDWOOD CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Proteograph® Product...
Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries
23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product Suite 23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product Suite
Seer, Inc. Transcript: TD Cowen 46th Annual Health Care Conference
Significant growth in instrument placements, consumable sales, and customer publications marked 2025, driven by innovative programs and workflow improvements. New detector technology and strong partnerships position the company for future expansion, despite ongoing macroeconomic headwinds.
The Radoff-JEC Group Sends Open Letter to Seer, Inc. Unconflicted Independent Directors Meeta Gulyani and Nicolas Roelofs
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 7.6% of the outstanding common sto...
Seer, Inc. Earnings Call Transcript: Q4 2025
Revenue grew 17% year-over-year to $16.6M in 2025, with strong gains in installed base and consumable kit volume, but results were impacted by delayed NIH funding and cautious customer spending. 2026 guidance is $16–18M, reflecting ongoing funding uncertainty and potential upside from new large-scale studies.
Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors un...
Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourt...
The Radoff-JEC Group Issues Open Letter to Seer Inc.'s Board of Directors Regarding the Immediate Need for Significant Change
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own nearly 7.5% of the outstanding common stock of S...
Leading Scientists Demonstrate How Seer's Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhga...
Seer to Participate in the TD Cowen 46th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be parti...
Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial ...
Nature Genetics Study Validates Seer's Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers
Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establish...
Seer, Inc. Transcript: CG MedTech, Diagnostics and Digital Health & Services Forum
Proteograph ONE and SP200 have enabled unprecedented scale and depth in proteomic studies, leading to major NIH selection, rapid customer adoption, and accelerating scientific publications. Strategic programs and partnerships are driving platform adoption, with strong financial discipline and innovation positioning for future growth.
Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025
Studies spanning cardiovascular, aging, and cancer biology highlight how Seer's Proteograph® platform is enabling discovery at population scale Studies spanning cardiovascular, aging, and cancer biolo...
Seer, Inc. Earnings Call Transcript: Q3 2025
Q3 2025 saw record instrument shipments, 2% revenue growth, and improved gross margin, despite macroeconomic and government funding headwinds. The Proteograph platform gained traction in large-scale studies and was selected for a major NIH-funded project.
Seer Reports Third Quarter 2025 Financial Results
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the third...
Seer to Participate in Upcoming November Investor Conferences
REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced company management will be par...
Seer to Report Third Quarter 2025 Financial Results on November 6, 2025
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial ...
Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025
Scientific presentations reveal how Seer's Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers Scientific...
Seer, Inc. Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Significant advances in proteomics technology have enabled large-scale, unbiased studies with improved speed, cost, and automation. Customer adoption is accelerating, driven by robust, reproducible data and workflow efficiency, while financial discipline supports ongoing innovation and share repurchases.
Seer Appoints Isaac Ro to its Board of Directors
REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to ...